Treatment of hind limb ischemia using angiogenic peptide nanofibers

Simple item page
dc.citation.firstpage113en_US
dc.citation.journalTitleBiomaterialsen_US
dc.citation.lastpage119en_US
dc.citation.volumeNumber98en_US
dc.contributor.authorKumar, Vivek A.en_US
dc.contributor.authorLiu, Qien_US
dc.contributor.authorWickremasinghe, Navindee C.en_US
dc.contributor.authorShi, Siyuen_US
dc.contributor.authorCornwright, Toya T.en_US
dc.contributor.authorDeng, Yuxiaoen_US
dc.contributor.authorAzares, Alonen_US
dc.contributor.authorMoore, Amanda N.en_US
dc.contributor.authorAcevedo-Jake, Amanda M.en_US
dc.contributor.authorAgudo, Noel R.en_US
dc.contributor.authorPan, Suen_US
dc.contributor.authorWoodside, Darren G.en_US
dc.contributor.authorVanderslice, Peteren_US
dc.contributor.authorWillerson, James T.en_US
dc.contributor.authorDixon, Richard A.en_US
dc.contributor.authorHartgerink, Jeffrey D.en_US
dc.date.accessioned2017-08-09T17:13:27Zen_US
dc.date.available2017-08-09T17:13:27Zen_US
dc.date.issued2016en_US
dc.description.abstractFor a proangiogenic therapy to be successful, it must promote the development of mature vasculature for rapid reperfusion of ischemic tissue. Whole growth factor, stem cell, and gene therapies have yet to achieve the clinical success needed to become FDA-approved revascularization therapies. Herein, we characterize a biodegradable peptide-based scaffold engineered to mimic VEGF and self-assemble into a nanofibrous, thixotropic hydrogel, SLanc. We found that this injectable hydrogel was rapidly infiltrated by host cells and could be degraded while promoting the generation of neovessels. In mice with induced hind limb ischemia, this synthetic peptide scaffold promoted angiogenesis and ischemic tissue recovery, as shown by Doppler-quantified limb perfusion and a treadmill endurance test. Thirteen-month-old mice showed significant recovery within 7 days of treatment. Biodistribution studies in healthy mice showed that the hydrogel is safe when administered intramuscularly, subcutaneously, or intravenously. These preclinical studies help establish the efficacy of this treatment for peripheral artery disease due to diminished microvascular perfusion, a necessary step before clinical translation. This peptide-based approach eliminates the need for cell transplantation or viral gene transfection (therapies currently being assessed in clinical trials) and could be a more effective regenerative medicine approach to microvascular tissue engineering.en_US
dc.identifier.citationKumar, Vivek A., Liu, Qi, Wickremasinghe, Navindee C., et al.. "Treatment of hind limb ischemia using angiogenic peptide nanofibers." <i>Biomaterials,</i> 98, (2016) Elsevier: 113-119. https://doi.org/10.1016/j.biomaterials.2016.04.032.en_US
dc.identifier.digitalTreatment_hind_limb_ischemiaen_US
dc.identifier.doihttps://doi.org/10.1016/j.biomaterials.2016.04.032en_US
dc.identifier.urihttps://hdl.handle.net/1911/96642en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsThis is an author's peer-reviewed final manuscript, as accepted by the publisher. The published article is copyrighted by Elsevier.en_US
dc.subject.keywordHind-limb ischemiaen_US
dc.subject.keywordMulti-domain peptideen_US
dc.subject.keywordPeripheral artery diseaseen_US
dc.subject.keywordSelf-assemblyen_US
dc.subject.keywordTherapeutic angiogenesisen_US
dc.titleTreatment of hind limb ischemia using angiogenic peptide nanofibersen_US
dc.typeJournal articleen_US
dc.type.dcmiTexten_US
dc.type.publicationpost-printen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Treatment_hind_limb_ischemia.pdf
Size:
810.49 KB
Format:
Adobe Portable Document Format
Download
Collections
Faculty Publications
Bioengineering Publications